-
Chinese Expertise at AASLD 2024: Dr. Qin Ning’s Team Achieves New Breakthroughs in CHB Clinical Cure Strategies
The second study evaluated the efficacy of a triple therapy combining TLR-7 agonist TQ-A3334, PD-L1 antibody TQ-B2450, and NA in virologically suppressed CHB patients. The results demonstrated that the triple…
-
Dr. Jun Guo: Reflecting on Progress in Renal Cancer Treatment and Pioneering a New Era of Cellular Therapy for Metastatic Patients
Renal cancer is one of the three major malignancies in the urinary system, with advanced metastatic renal cancer having a poor prognosis and an overall five-year survival rate of less than 20%. Recent advances in targeted therapies and immunotherapies have led to significant improvements in treatment outcomes; however, for patients progressing beyond first-line therapies, the…
-
Dr. Kan Gong: Reflecting on Key Challenges and Hotspots in Renal Cancer Diagnosis and Treatment in China, Exploring New Frontiers in Translational Research | The 8th West China Uro-Oncology Tianfu Academic Conference
Renal cancer is one of the three major malignancies in the urinary system. Early-stage renal cancer often presents with concealed symptoms, making it difficult to differentiate between benign and malignant tumors. Advanced renal cancer primarily relies on targeted or immunotherapy, yet the effectiveness of existing targeted drugs is low, and resistance tends to develop easily.…
-
Ten Years of Progress in Standardization: Key Updates to the 2024 Chinese Guidelines for Advanced Breast Cancer Treatment
At the 2024 Breast Cancer Standardized Diagnosis and Treatment & Quality Control Conference (November 8–10, Beijing), Dr. Ying Fan from the Cancer Hospital Chinese Academy of Medical Sciences, presented the key updates to the 2024 Chinese Advanced Breast Cancer Clinical Guidelines (ABCC). The updated ABCC guidelines include treatment recommendations for different breast cancer subtypes and…
-
Strengthening Global Bonds in Cancer Control: Highlights from the CACA-SLACOM and CACA-SIS Summits
The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the 4th Asian Oncology Summit (AOS), hosted by the Chinese Anti-Cancer Association (CACA) in collaboration with the Chinese Academy of Integrative Medicine and the Shaanxi Anti-Cancer Association, took place from November 14–17 in the ancient city of Xi’an. This prestigious event featured specialized summits co-organized…
-
CSCO 2024丨Dr. Wenhua Liang: Collaborative Efforts — Exploring New Precision Medicine Pathways for NSCLC in the Era of Immunotherapy
The 27th National Conference of Clinical Oncology and 2024 CSCO Academic Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Xiamen from September 25 to 29, 2024. The conference included multiple sessions on lung cancer, which brought together the latest advances…
-
ESMO 2024丨Unveiling the “Genetic Map” of Pancreatic Cancer: How Driver Mutations Guide Personalized Treatment
At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, in the session dedicated to basic science and translational research, researchers presented groundbreaking findings on driver mutations in pancreatic cancer and their role in predicting patient prognosis and treatment response. The research highlighted significant differences in the diversity of driver gene mutations between healthy…
-
ESMO 2024丨Dr. Antonio Passaro: Zipalertinib Shows Promising Efficacy and Safety in EGFR Exon 20 Insertion-Mutant NSCLC Patients
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain, where several significant advances in lung cancer research were presented. Dr. Antonio Passaro from the European Institute of Oncology Division of Thoracic Oncology in Milan, Italy, shared insights on the safety and antitumor activity of…
Connecting Medical Expertise through Media